99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
On Wednesday, Eli Lilly And Co (NYSE:LLY) released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.
禮來週三發佈了第3期SURMOUNt-1三年研究(176周治療期)的詳細結果，這是迄今爲止完成時間最長的提澤帕肽研究。
Weekly tirzepatide (Zepbound and Mounjaro) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks.
每週注射 tirzepatide（Zepbound 和 Mounjaro）（合併 5 mg、10 mg、15 mg 劑量）在176周內顯著減少了患有糖尿病前期和肥胖或超重的成年人發展爲2型糖尿病的風險，與安慰劑相比。
Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period for the efficacy estimandi.
tirzepatide 在三年的治療期間（15 mg 劑量）表現出持續的平均體重下降 22.9%。
Also Read: Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
另請閱讀：禮來第三季度業績：Mounjaro 銷售額超過翻倍，利潤受到 29.8億 美元的打擊，下調年度展望，股票大跌。
"Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years while benefitting from a substantial decrease in risk of developing type 2 diabetes. In absolute terms, nearly 99% of individuals treated with tirzepatide remained diabetes-free at 176 weeks," said Ania Jastreboff, director of the Yale Obesity Research Center.
「接受 tirzepatide 治療的個體平均體重減少了 23%，並在三年內維持這一水平，同時顯著降低了發展爲2型糖尿病的風險。在絕對值上，近 99% 的接受 tirzepatide 治療的個體在 176 周時仍然沒有患糖尿病，」耶魯大學肥胖研究中心的董事 Ania Jastreboff 說。
"In the SURMOUNT-1 three-year study of tirzepatide, an average weight reduction of up to 22.9% was accompanied by a hazard ratio of 0.06 for progression to type 2 diabetes. This translates to a risk reduction of 94% and a number needed to treat of nine to prevent one case of diabetes," said Jeff Emmick, SVP of product development at Eli Lilly.
「在 tirzepatide 的 SURMOUNt-1 三年研究中，平均體重降低高達 22.9%，伴隨發展爲2型糖尿病的危險比爲 0.06。這轉化爲94%的風險降低，以及需要治療九人以預防一例糖尿病，」禮來產品開發高級副總裁 Jeff Emmick 說。
At 193 weeks, 2.4% of patients on Lilly's tirzepatide were diagnosed with Type 2 diabetes compared to 13.7% of patients in the placebo group.
在 193 周時，使用禮來的 tirzepatide 的患者中 2.4% 被診斷爲2型糖尿病，而安慰劑組的患者中則爲 13.7%。
In additional endpoints, the study showed an association of tirzepatide treatment with improved glycemic control, cardiometabolic risk factors (including fasting insulin, blood pressure, and lipids), and health-related quality of life sustained through 176 weeks.
在其他終點上，研究顯示 tirzepatide 治療與改善糖代謝控制、心臟代謝風險因素（包括空腹胰島素、血壓和血脂）以及持續 176 周的健康相關生活質量有關。
A post hoc mediation analysis suggested that approximately half of the observed effect in a delay to onset of type 2 diabetes with tirzepatide was associated with medication-induced weight reduction.
後驗中介分析表明，約一半觀察到的tirzepatide延緩2型糖尿病發作的效果與藥物誘導的體重減輕有關。
Price Action: LLY stock is down 2.21% at $793.97 at the last check on Thursday.
價格動態：禮來股票在週四最後一次檢查時下跌2.21%，報$793.97。
- Salesforce CEO Marc Benioff Bets Big on Billion Bots
- 賽富時CEO馬克·貝尼奧夫大舉投資於數十億個機器人
Image by Mohammed_Al_Ali via Shutterstock
圖片來自Shutterstock的Mohammed_Al_Ali。
